SEC Form 4 · STOCK Act

Insider buys that paid off for the people who copied them.

ZeroStack Corp.

+206.0%

Michael Heinrich, Executive Chair, bought $3.5M. Filed Jul 20, 6:31 PM ET.

$1,000 copied at the first price after the filing (Jul 21 open, $1.66) was $3,060 30 trading days later.

Example. Of 339 buys of $100K or more filed Jun 29 to Sep 11, the median lost 5.3% and 67.8% lost money over the same 30 trading days. Not investment advice.

Officers and directors must report their own stock purchases within two business days. We list every one, largest first, with what copying it would have returned.

A free account keeps a watchlist. No password: we email you a link.

4 h delay

Buys Sells Buys and sells Any size $100K+$1M+

Pro filters

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$127K−11.8%Oct 19

ARQTSell

Arcutis Biotherapeutics, Inc.

Masaru Matsuda · Insider

$92K−3.2%Sep 18

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$114K−11.7%Sep 17

ARQTSell

Arcutis Biotherapeutics, Inc.

Masaru Matsuda · Insider

$250K−7.9%Sep 10

ARQTSell

Arcutis Biotherapeutics, Inc.

Terrie Curran · Director

$956K−61.9%Aug 28

ARQTSell

Arcutis Biotherapeutics, Inc.

Terrie Curran · Director

$28K−4.4%Aug 24

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$46K−1.4%Aug 21

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$124K−11.5%Aug 19

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$395K−11.2%Aug 14

ARQTSell

Arcutis Biotherapeutics, Inc.

Masaru Matsuda · Insider

$32K−1.0%Aug 6

ARQTSell

Arcutis Biotherapeutics, Inc.

Todd Watanabe · Insider

$114K−0.6%Aug 6

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$127K−11.3%Jul 17

ARQTSell

Arcutis Biotherapeutics, Inc.

Sue-Jean Lin · Director

$121K−15.2%Jun 18

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$116K−11.1%Jun 18

ARQTSell

Arcutis Biotherapeutics, Inc.

Masaru Matsuda · Insider

$192K−6.0%May 6

ARQTSell

Arcutis Biotherapeutics, Inc.

Latha Vairavan · SVP CFO

$32K−2.0%May 6

ARQTSell

Arcutis Biotherapeutics, Inc.

Todd Watanabe · Insider

$75KMay 6

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$164K−18.0%May 5

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$239K−20.0%Apr 3

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$257K−17.0%Mar 4

ARQTSell

Arcutis Biotherapeutics, Inc.

Keith R Leonard · Director

$997K−62.0%Mar 4

ARQTSell

Arcutis Biotherapeutics, Inc.

Todd Watanabe · Insider

$941K−4.0%Mar 3

ARQTSell

Arcutis Biotherapeutics, Inc.

Masaru Matsuda · Insider

$314K−8.0%Mar 3

ARQTSell

Arcutis Biotherapeutics, Inc.

Latha Vairavan · SVP CFO

$72K−3.0%Mar 3

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$158K−5.0%Mar 3

ARQTSell

Arcutis Biotherapeutics, Inc.

Larry Todd Edwards · Insider

$93K−2.0%Mar 3

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$72K−3.0%Jan 7

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$290K−13.0%Jan 6

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$50K−2.0%Jan 2

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$333K−10.0%Dec 17

ARQTSell

Arcutis Biotherapeutics, Inc.

Masaru Matsuda · Insider

$50K−1.0%Dec 3

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$302K−11.0%Dec 3

ARQTSell

Arcutis Biotherapeutics, Inc.

Sue-Jean Lin · Director

$778K−49.0%Nov 25

ARQTSell

Arcutis Biotherapeutics, Inc.

Todd Watanabe · Insider

$1.5M−5.0%Nov 24

ARQTSell

Arcutis Biotherapeutics, Inc.

Masaru Matsuda · Insider

$72K−2.0%Nov 21

ARQTSell

Arcutis Biotherapeutics, Inc.

Halley E Gilbert · Director

$455K−43.0%Nov 21

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$163K−11.0%Nov 26

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$713K−35.0%Nov 18

ARQTSell

Arcutis Biotherapeutics, Inc.

Terrie Curran · Director

$94K−46.0%Nov 13

ARQTSell

Arcutis Biotherapeutics, Inc.

Masaru Matsuda · Insider

$44K−3.0%Nov 5

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$87K−5.0%Nov 5

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$134K−8.0%Nov 5

ARQTSell

Arcutis Biotherapeutics, Inc.

Todd Franklin Watanabe · Insider

$120K−1.0%Nov 5

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$93K−5.0%Oct 3

ARQTSell

Arcutis Biotherapeutics, Inc.

Larry Todd Edwards · SVP Chief Commercial Officer

$37K−3.0%Oct 3

ARQTSell

Arcutis Biotherapeutics, Inc.

David Joseph Topper · CFO

$110K−7.0%Sep 25

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$108K−5.0%Sep 5

ARQTSell

Arcutis Biotherapeutics, Inc.

Masaru Matsuda · Insider

$47K−3.0%Aug 5

ARQTSell

Arcutis Biotherapeutics, Inc.

Patrick Burnett · Insider

$119K−6.0%Aug 5

ARQTSell

Arcutis Biotherapeutics, Inc.

Howard G. Welgus · Director

$99K−5.0%Aug 5

Older filings

Filings come from SEC EDGAR within a minute of the SEC accepting them. Without Pro, each one unlocks 4 hours later. Not investment advice.

Questions

Where does the data come from?

Corporate insider trades come straight from SEC Form 4 filings, pulled from EDGAR within a minute of each filing. Congress trades come from STOCK Act disclosures. All of it is public and free to browse here, and Pro sees the newest filings first.

How often is it updated?

Every minute from 6 AM to 10 PM New York time on weekdays, the hours the SEC accepts filings. Pro sees each filing as it lands. Without Pro, a filing unlocks 4 hours after the SEC accepts it.

Is following insider trades legal?

Yes. Insiders are legally required to disclose their trades within a few days. Acting on those public disclosures is completely legal. Trading on private, non-public information is illegal, but that's a different thing.

What does the iPhone app add?

We're building an iPhone app that alerts you to new filings and, if you choose, copies a buy into your own brokerage after you approve it. It isn't out yet, and the waitlist is free.